In the latest period of Q4'25, RXRX's Gross Margin reached 59.8%, marking a strong recovery from negative territory, while Operating Margin improved to -3.05% and Net Profit Margin stood at -3.04%, reflecting ongoing operational challenges but a notable narrowing of losses compared to prior quarters. Over the period from Q1'23 to Q4'25, the chart reveals volatile trends across all margins, with Gross Margin fluctuating between deep negatives like -18.4% in Q4'24 and highs of 53.7% in Q3'24, indicating inconsistent cost management in a biotech context. Operating and Net Profit Margins consistently remained negative, deteriorating to extremes such as -40.4% and -39.4% in Q4'24 before partial rebounds, underscoring persistent high expenses and R&D investments that have hindered profitability despite occasional improvements in gross efficiency.